Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

What happened

Faeth Therapeutics added Adam Schayowitz to its board as a Class III director starting October 23, 2026. He is a senior research and development leader at Zymeworks with about 20 years of cancer drug development experience. He also received an option for 25,000 shares that vests monthly over three years if he stays.

Global impact / market context

A board member with deep cancer drug experience can shape how the company decides which treatments to pursue. Ordinary investors get a small signal about the company's focus and oversight, but no financial results or product updates were shared.

What to watch

1. Check for company statements about what Schayowitz will do on the board, because his specific role is not yet described.
2. Watch for updates on the 25,000-share option, because it ties his pay to staying on and can affect share count over time.
3. Look for any future company disclosures about board decisions or drug programs, because board changes alone do not show business performance.

Affected assets

• Zymeworks Inc.

Evidence

• Infoway News — Faeth Therapeutics appoints Adam Schayowitz to its board 2026-10-27T11:43:00+00:00
• Infoway News — Faeth Appoints Adam Schayowitz to Bd of Directors 2026-10-27T11:02:00+00:00
• Infoway News — Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors 2026-10-27T11:00:00+00:00
• Incident timeline — Faeth Therapeutics appoints Adam Schayowitz to its board
• Incident timeline — Faeth Appoints Adam Schayowitz to Bd of Directors
• Incident timeline — Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors